These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 2053921)

  • 1. The pharmacokinetics of total and unbound concentrations of tenoxicam in synovial fluid and plasma.
    Day RO; Williams KM; Graham S; Handel M
    Arthritis Rheum; 1991 Jun; 34(6):751-60. PubMed ID: 2053921
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Integrated plasma and synovial fluid pharmacokinetics of tenoxicam in patients with rheumatoid arthritis and osteoarthritis: factors determining the synovial fluid/plasma distribution ratio.
    Hinderling PH; Hartmann D; Crevoisier C; Moser U; Heizmann P
    Ther Drug Monit; 1988; 10(3):250-60. PubMed ID: 3262939
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A pharmacokinetic comparison of tenoxicam in plasma and synovial fluid.
    Bird HA; Allen JG; Dixon JS; Wright V
    Eur J Rheumatol Inflamm; 1985; 8(1):47-52. PubMed ID: 3879830
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A pharmacokinetic comparison of tenoxicam in plasma and synovial fluid.
    Bird HA; Allen JG; Dixon JS; Wright V
    Br J Rheumatol; 1985 Nov; 24(4):351-6. PubMed ID: 3877538
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Single and multiple dose pharmacokinetics of tenoxicam in the elderly.
    Nilsen OG; Walstad RA; Eckert M; Heizmann P; Bückert A; Am T; Løge I; Unnvik J; Thue E
    Eur J Clin Pharmacol; 1988; 35(5):563-6. PubMed ID: 3266152
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Plasma tenoxicam concentrations after single and multiple oral doses.
    Crevoisier C; Heizmann P; Forgo I; Dubach UC
    Eur J Drug Metab Pharmacokinet; 1989; 14(1):23-7. PubMed ID: 2788089
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tenoxicam concentrations in synovium and joint cartilage in humans.
    Bannwarth B; Netter P; Lapicque F; Mainard D; Fener P; Gillet P; Gaucher A
    Agents Actions; 1991 Mar; 32(3-4):295-8. PubMed ID: 1862747
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical pharmacokinetics of tenoxicam.
    Nilsen OG
    Clin Pharmacokinet; 1994 Jan; 26(1):16-43. PubMed ID: 8137596
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacokinetics of oxicam nonsteroidal anti-inflammatory agents.
    Olkkola KT; Brunetto AV; Mattila MJ
    Clin Pharmacokinet; 1994 Feb; 26(2):107-20. PubMed ID: 8162655
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tenoxicam: acute dose-dependent disposition studies in rats.
    Lopez-Bustamante LG; Troconiz JI; Fos D
    J Pharm Sci; 1993 Aug; 82(8):851-3. PubMed ID: 8377127
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacokinetics of tenoxicam at different dosage regimes.
    Scaglione F; Demartini G; Dugnani S; Fraschini F; Triscari FA
    Farmaco; 1993 Sep; 48(9):1321-5. PubMed ID: 8259988
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Overview on the pharmacokinetics of tenoxicam.
    Guentert TW; Heintz RC; Joly R
    Eur J Rheumatol Inflamm; 1987; 9(2):15-25. PubMed ID: 3329107
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The influence of cholestyramine on the elimination of tenoxicam and piroxicam.
    Guentert TW; Defoin R; Mosberg H
    Eur J Clin Pharmacol; 1988; 34(3):283-9. PubMed ID: 3260866
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Plasma and synovial fluid concentrations of piroxicam during prolonged treatment with piroxicam pivalic ester.
    Chérié Lignière G; Montagnani G; Alberici M; Acerbi D
    Arzneimittelforschung; 1987 May; 37(5):560-3. PubMed ID: 3619977
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Single- and multiple-dose pharmacokinetics, kidney tolerability and plasma protein binding of tenoxicam in renally impaired patients and healthy volunteers.
    Nilsen OG; Aasarød K; Widerøe TE; Guentert TW
    Pharmacol Toxicol; 2001 Nov; 89(5):265-72. PubMed ID: 11881981
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The effect of haemodialysis on the pharmacokinetics of tenoxicam in patients with end-stage renal disease.
    al-Ghamdi MS; al-Mohanna FA; al-Mustafa ZH; al-Saeed IS
    Eur J Clin Pharmacol; 1992; 43(2):197-9. PubMed ID: 1425878
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Neither cimetidine nor probenecid affect the pharmacokinetics of tenoxicam in normal volunteers.
    Day RO; Geisslinger G; Paull P; Williams KM
    Br J Clin Pharmacol; 1994 Jan; 37(1):79-81. PubMed ID: 8148224
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Indirect assessment of the enterohepatic recirculation of piroxicam and tenoxicam.
    Benveniste C; Striberni R; Dayer P
    Eur J Clin Pharmacol; 1990; 38(6):547-9. PubMed ID: 2373127
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacokinetics of tenoxicam in healthy human volunteers.
    Heintz RC; Guentert TW; Enrico JF; Dubach UC; Brandt R; Jeunet FS
    Eur J Rheumatol Inflamm; 1984; 7(2):33-44. PubMed ID: 6336292
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Influence of liver cirrhosis upon the pharmacokinetics of tenoxicam.
    Crevoisier C; Zaugg PY; Heizmann P; Meyer J
    Int J Clin Pharmacol Res; 1989; 9(5):327-34. PubMed ID: 2625372
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.